Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome
Clinical Gastroenterology and Hepatology · 2024
DOI: 10.1016/j.cgh.2023.02.014 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024. Verfasst von Vivek C Goodoory und 3 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Gastroenterology Institute, St James's University Hospital, Leeds, United Kingdom; Leeds Institute of Medical Research at St. James's, Universi…. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tillotts Pharma.
Abstract (Originalsprache)
BACKGROUND & AIMS: Some patients with irritable bowel syndrome (IBS) demonstrate low-grade inflammation in the intestine. Mesalamine, which has anti-inflammatory effects, may be an efficacious treatment for IBS, but studies are conflicting. We conducted a systematic review and meta-analysis to assess efficacy and safety of mesalamine in IBS. METHODS: We searched the medical literature up to September 14, 2022, to identify randomized controlled trials (RCTs) of mesalamine in IBS. We judged efficacy and safety using dichotomous assessments of effect on global IBS symptoms, abdominal pain, bowel habit or stool frequency, and occurrence of any adverse event. We pooled data using a random effects model, with efficacy and safety reported as pooled relative risks (RRs) with 95% confidence intervals (CIs). RESULTS: We identified 8 eligible RCTs (820 patients). Mesalamine was more efficacious than placebo for global IBS symptoms (RR of global symptoms not improving, 0.86; 95% CI, 0.79-0.95; number needed to treat = 10; 95% CI, 6-27), but not for abdominal pain or bowel habit or stool frequency. Subgroup analyses demonstrated efficacy of mesalamine in IBS with diarrhea for global IBS symptoms (RR, 0.88; 95% CI, 0.79-0.99), but not patients with other predominant bowel habits or those with post-infection IBS. Adverse event rates were no higher with mesalamine (RR, 1.20; 95% CI, 0.89-1.63) but were reported in only 5 trials. CONCLUSIONS: Mesalamine may be modestly efficacious for global symptoms in IBS, particularly IBS with diarrhea, but quality of evidence was low. Adequately powered high quality RCTs of mesalamine in IBS are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leeds Gastroenterology Institute, St James's University Hospital, Leeds, United Kingdom; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom.
- Division of Gastroenterology, Hepatology & Nutrition, University of Utah, Salt Lake City, Utah; George E. Wahlen V.A. Medical Center, Salt Lake City, Utah.
- Leeds Gastroenterology Institute, St James's University Hospital, Leeds, United Kingdom; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom. Electronic address: alexf12399@yah…
Förderung
- Tillotts Pharma
Zitieren
APA
Goodoory, V. C., Tuteja, A. K., Black, C. J., & Ford, A. C. (2024). Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.02.014
Vancouver
Goodoory VC, Tuteja AK, Black CJ, Ford AC. Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology. 2024. doi:10.1016/j.cgh.2023.02.014
BibTeX
@article{Goodoory2024,
author = {Goodoory, Vivek C and Tuteja, Ashok K and Black, Christopher J and Ford, Alexander C},
title = {Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
doi = {10.1016/j.cgh.2023.02.014}
}
EUVIMED